Stockreport

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF central nervous system lymphoma (PCNSL), each with central nervous system (CNS) involvement Data presented at the American Association for Cancer Research (AACR) 2024 [Read more]